Vanguard Group
GLMD icon

Vanguard Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Vanguard Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-177
Closed -$242K – 4144
2015
Q4 		$242K Buy
177
+15
+9% +$23.9K ﹤0.01% 3987
2015
Q3 		$217K Buy
162
+17
+12% +$28K ﹤0.01% 4018
2015
Q2 		$262K Buy
145
+50
+53% +$87K ﹤0.01% 3999
2015
Q1 		$160K Buy
+95
New +$143K ﹤0.01% 4026

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

Vanguard Group's GLMD Position: Q1 2016 in Review

Vanguard Group sold out of Galmed Pharmaceuticals (GLMD) in Q1 2016, closing a stake of 177 shares — an estimated $242K sold.

Vanguard Group first reported a position in GLMD in Q1 2015 and held it in 4 quarters. The position peaked at $262K in Q2 2015. 18 funds tracked by Wall St. Rank hold GLMD as of Q1 2016.

  • Vanguard Group reported no remaining Galmed Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Vanguard Group sold 177 Galmed Pharmaceuticals shares in Q1 2016, an estimated $242K.
  • Vanguard Group first reported a position in Galmed Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Vanguard Group's Galmed Pharmaceuticals position peaked at $262K in Q2 2015.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2016.

Based on Vanguard Group's 13F filing for Q1 2016, filed 13 May 2016.